Argus reported on Thursday that it has increased its price target on healthcare product company, Johnson & Johnson (JNJ).
The firm has maintained a “Buy” rating on JNJ, and has increased its price target from $80 to $96. This price target suggests a 13% upside from the stock’s current price of $83.53.
Johnson & Johnson shares were mostly flat during Thursday morning trading. The stock has increased 32% in the past year.
The Bottom Line
Shares of Johnson & Johnson (JNJ) have a 2.91% yield, based on Thursday morning’s price of $83.71.
Johnson & Johnson (JNJ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.